FGL
| Category | Compounds |
|---|---|
| Also known as | FGL Peptide, NCAM-derived FGL |
| Last updated | 2026-04-14 |
| Reading time | 2 min read |
| Tags | neurotrophicncam-mimeticcognitionresearch |
Overview
FGL is a short synthetic peptide derived from the second fibronectin type-III module of the neural cell adhesion molecule (NCAM), a protein centrally involved in synaptic development, plasticity, and memory. FGL mimics the NCAM region that interacts with fibroblast growth factor receptor (FGFR1), allowing the small peptide to engage a core signaling pathway that NCAM normally activates through cell-to-cell contact.
Published preclinical research on FGL (often written as FGL peptide) describes cognitive enhancement, neuroprotection against β-amyloid and ischemic insults, and anti-inflammatory activity in neural tissue. Because FGFR1 signaling drives trophic responses in many neuron populations, FGL has been explored as a candidate for Alzheimer's disease, stroke, and psychiatric conditions.
FGL is commonly discussed alongside other neurotrophic research peptides such as P21 peptide, Dihexa, Cerebrolysin, and Russian-developed neuropeptides like Semax and Noopept.
Structure / Chemistry
FGL is a 15-residue synthetic peptide corresponding to the FGFR-binding site within NCAM's second F3 module (sequence beginning with EVYVVAENQQGKSKA). Variants include dendrimeric forms used in some preclinical studies to enhance potency and stability.
Mechanism of Action
FGL binds and activates FGFR1, triggering downstream signaling cascades including ERK1/2 and PI3K/AKT that promote neurite outgrowth, synaptic plasticity, and neuronal survival. Because NCAM-FGFR interactions are central to hippocampal plasticity and memory consolidation, FGL effectively pharmacologically mimics a physiological trophic signal.
Research Summary
| Area | Finding | Reference |
|---|---|---|
| Memory | Memory enhancement in rodent tasks | Cambon et al., J Neurosci 2004 |
| Alzheimer's model | Protection against amyloid toxicity | Klementiev et al., Neuroscience 2007 |
| Stroke | Neuroprotection in ischemia models | Skibo et al., Neurosci Lett 2005 |
| Inflammation | Anti-inflammatory effects in CNS | Secher et al., J Neuroinflammation 2006 |
| Design | NCAM-derived FGFR-binding peptide | Kiselyov et al., Structure 2003 |
Pharmacokinetics
FGL has been administered in rodent studies by intranasal, intraperitoneal, and intravenous routes. Reported plasma half-life is short, but biological effects persist beyond plasma exposure because of downstream signaling cascades. Human pharmacokinetic data are limited.
Common Discussion Topics
- Relationship to NCAM biology and synaptic plasticity.
- FGFR1 as a small-molecule vs. peptide target.
- Comparative positioning with P21 peptide and Dihexa.
- Intranasal vs. systemic administration strategies.
- Translation of rodent findings to clinical neurodegeneration research.
Related Compounds
Sourcing research-grade compounds
Obtaining high-purity, research-grade FGL requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing FGL. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Cerebrolysin— A porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, approved in over 40 countries for stroke, traumatic brain injury, and dementia, though not FDA-approved in the United States.
- Dihexa— A hexapeptide analog of angiotensin IV reported to be up to seven times more potent than BDNF at promoting hepatocyte growth factor signaling, studied primarily for cognitive enhancement and synaptogenesis in animal models.
- Noopept— Noopept is a synthetic proline-containing dipeptide nootropic developed in Russia, often discussed as a more potent, orally active analog of piracetam.
- P21 Peptide— P21 is a CNTF-derived tetrapeptide designed to mimic the active region of ciliary neurotrophic factor, studied for neurogenesis and Alzheimer's disease models.
- Semax— A synthetic heptapeptide analog of ACTH(4-10) developed in Russia as a nootropic and neuroprotective agent, studied for cognitive enhancement, stroke recovery, and BDNF modulation.